|
ALLO | Allogene Therapeutics, Inc. |
|
|
ALLO | Allogene Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 1.32 |
| Leverage | 21.28% |
| Market Cap | $ 351.7m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -281.8m |
| Margin | -13339.18% |
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.